Posted by Michael Wonder on 19 Mar 2018
Outcome statement - Feb 2018 Drug Utilisation Sub Committee meeting
16 March 2018 - The outcome statement from the February 2018 Drug Utilisation Sub Committee meeting is now available.
DUSC reviewed the utilisation of the following PBS medicines in February 2018:
- Ivacaftor for cystic fibrosis
- Cetuximab, bevacizumab and panitumumab for metastatic colorectal cancer
- Trastuzumab, pertuzumab and trastuzumab emtansine for metastatic breast cancer
